The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
Open accessAbstract
Objectives: To estimate the economic efficiency of tight blood pressure control, with angiotensin converting enzyme inhibitors or β blockers, compared with less tight control in hypertensive patients with type 2 diabetes. Design: Cost effectiveness analysis incorporating within trial analysis and estimation of impact on life expectancy through use of the within trial hazards of reaching a defined clinical end point. Use of resources driven by trial protocol and use of resources in standard clinical practice were both considered. Setting: 20 hospital based clinics in England, Scotland, and Northern Ireland. Subjects: 1148 hypertensive patients with type 2 diabetes from UK prospective diabetes study randomised to tight control of blood pressure (n=758) or less tight control (n=390). Main outcome measure: Cost effectiveness ratios based on ( a ) use of healthcare resources associated with tight control and less tight control and treatment of complications and ( b ) within trial time free from diabetes related end points, and life years gained. Results: Based on use of resources driven by trial protocol, the incremental cost effectiveness of tight control compared with less tight control was cost saving. Based on use of resources in standard clinical practice, incremental cost per extra year free from end points amounted to £1049 (costs and effects discounted at 6% per year) and £434 (costs discounted at 6% per year and effects not discounted). The incremental cost per life year gained was £720 (costs and effects discounted at 6% per year) and £291 (costs discounted at 6% per year and effects not discounted). Conclusions: Tight control of blood pressure in hypertensive patients with type 2 diabetes substantially reduced the cost of complications, increased the interval without complications and survival, and had a cost effectiveness ratio that compares favourably with many accepted healthcare programmes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
Costs, effects and C/E‐ratios alongside a clinical trial
Van Hout, B. A., Al, M. J., Gordon, G. S., & Rutten, F. F. H. (1994) · Health Economics · doi:10.1002/hec.4730030505 · Cited by 964
Eastman, R. C., Javitt, J. C., Herman, W. H., Dasbach, E. J., Copley-Merriman, C., Maier, W., Dong, F., Manninen, D., Zbrozek, A. S., Kotsanos, J., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.735 · Cited by 333
ESTIMATING CONFIDENCE INTERVALS FOR COST-EFFECTIVENESS RATIOS: AN EXAMPLE FROM A RANDOMIZED TRIAL
CHAUDHARY, M. A., & STEARNS, S. C. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19960715)15:13<1447::aid-sim267>3.0.co;2-v · Cited by 313
Long-term Cost-effectiveness of Various Initial Monotherapies for Mild to Moderate Hypertension
Edelson, J. T. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03440030094028 · Cited by 278
The Distribution of Health Care Costs and Their Statistical Analysis for Economic Evaluation
Briggs, A., & Gray, A. (1998) · Journal of Health Services Research & Policy · doi:10.1177/135581969800300410 · Cited by 272
Model of Complications of NIDDM: I. Model construction and assumptions
Eastman, R. C., Javitt, J. C., Herman, W. H., Dasbach, E. J., Zbrozek, A. S., Dong, F., Manninen, D., Garfield, S. A., Copley-Merriman, C., Maier, W., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.725 · Cited by 258
Confidence intervals for cost-effectiveness ratios: An application of Fieller's theorem
Willan, A. R., & OʼBrien, B. J. (1996) · Health Economics · Cited by 189
Cited by
Adler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133
Herman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R. F., Ackermann, R. T., Engelgau, M. M., Ratner, R. E., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00007 · Cited by 703
Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review
Li, R., Zhang, P., Barker, L. E., Chowdhury, F. M., & Zhang, X. (2010) · Diabetes Care · doi:10.2337/dc10-0843 · Cited by 491
Generalisability in economic evaluation studies in healthcare: a review and case studies
Sculpher, M., Pang, F., Manca, A., Drummond, M., Golder, S., Urdahl, H., Davies, L., & Eastwood, A. (2004) · Health Technology Assessment · doi:10.3310/hta8490 · Cited by 441
The Treatment of Hypertension in Adult Patients With Diabetes
Arauz-Pacheco, C., Parrott, M. A., & Raskin, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.134 · Cited by 326
Metadata
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1998-09-12
- Volume
- 317
- Issue
- 7160
- Pages
- 720-726
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W4246362004
- Cited by
- 303
- References
- 13
- FWCI
- 66.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. https://app.cochat.ai/papers/10.1136/bmj.317.7160.720
- The paper
- Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. (1998). BMJ. https://doi.org/10.1136/bmj.317.7160.720
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
